semaglutide/nad+/cyanocobalamin FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products Semaglutide + Vit. B12 CAPS
Description
Adverse events and tolerability The overall proportion of participants experiencing AEs while on treatment was slightly higher for oral semaglutide 7 mg and 14 mg than for oral semaglutide 3 mg and sitagliptin 100 mg, with most AEs being mild/moderate in severity (Table 3)
Clinical trial population adjacent: Obese individuals with higher adiposity, MASLD, T2D/high HbA1c, and/or significant liver fat and metabolic panel improvement goals
A summary of these cutaneous reactions is presented in Table 1
Many users report that gastrointestinal side effects are most pronounced when starting and tend to diminish over time
